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Abstract: 
Aim:To investigate the clinicopathological characteristics and survival of squamous cell carcinoma and 
adenocarcinoma the cervix using Surveillance, Epidemiology, and end Results database. Method:Patients with a 
diagnosis of squamous cell carcinoma and adenocarcinoma of the cervix were included between 2014 and 2019. 
Kaplan-Meier method and Cox regression models were used. Result: A total of 186 patients were included in this 
studyof which patients with known International Federation of Gynecology and Obstetrics stage and tumor grade, the 
stage III disease was diagnosed in 9.6% patients, and 26.46% patients had poorly or undifferentiated histology and 
well differentiated are 67.72%. The cumulative 5-year survival rates for stages Ib, II, and III/IVa disease were 93.5, 
77.0, and 60.3%, respectively. Conclusion: In multivariate analysis, the survival outcome of the patients remained 
high in the study that is mostly due to more patients of primary stages also the survival is associated with age. 
Squamous cell carcinoma is common and has aggressive characteristics, prone to metastasize and is dismal in 
prognosis compere to adenocarcinoma of the cervix.  
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INTRODUCTION:  
Cervical cancer is a cancer arising from the cervix. It 
is due to the abnormal growth of cells that have the 
ability to invade or spread to other parts of the body. 
Early on, typically no symptoms are seen. Later 
symptoms may include abnormal vaginal bleeding, 
pelvic pain, or pain during sexual intercourse. About 
90% of cervical cancer patients are squamous cell 
carcinoma. Adenocarcinoma of the cervix is a rare 
disease accounting for approximately 1-2% of uterine 
cervix malignancies [1] [3]. 
Cervical malignant growth is a standout amongst the 
most well-known tumors in ladies around the world. 
Notwithstanding overall endeavors at screening with 
the point of identifying cervical disease in the 
beginning period, numerous malignant growths are not 
found until effectively progressed. Customarily, 
radical hysterectomy or radiation treatment alone has 
been acknowledged as standard treatment for 
beginning time obtrusive cervical malignancy, and 
privately propelled disease has been treated by 
radiotherapy alone comprising of a mix of high-
portion rate intracavitary brachytherapy (ICBT) and 
outside bar radiotherapy (EBRT) (Okuma et al, 2015; 
Badakh et al, 2014;Tantivatana et al, 2018; Shwartz et 
al 2015). 
In the previous couple of years, significant advances 
in the administration of privately progressed cervical 
disease have been accounted for. Five randomized 
preliminaries demonstrated improved survival and 
nearby control when cisplatin-based chemotherapy 
was added simultaneously to radiation treatment in 
patients with privately progressed cervical disease 
(Cho et al, 2018; Pervin et al, 2019; Zamorano et al, 
2017; Lee et al, 2017; Tewari et al, 2014).This joined 
methodology approach delivered a flat out increment 
in 5-year survival of 12% as contrasted and radiation 
treatment alone and brought about an unexpected 
change in the standard of consideration for this 
malady. Presently that simultaneous treatment with 
cisplatin-based chemotherapy and radiotherapy is the 
standard treatment for privately progressed cervical 
malignant growth, the fundamental issue in treatment 
is the means by which chemotherapy is utilized, very 
little consideration is given to the radiotherapy 
strategy [5] [6]. 
Invasive cervical cancer (ICC) ranks third as the most 
common malignancy and fourth as the cause of 
cancer-related deaths among women 
worldwide.Despite population-based screening and 
development of advanced medical treatments, the 
morbidity of ICC is still common in developing 
countries like China, yielding 132,300 new cases each 
year. 
Currently, adenocarcinoma (ADC) receives the same 
standard treatments as squamous cell carcinoma 
(SCC): radical hysterectomy, radical hysterectomy 
followed by adjuvant radiotherapy (RT) or primary RT 
for early-stage carcinoma. Concurrent 
chemoradiotherapy (CCRT), which is recommended 
in cases of locally advanced cancer and for patients 
with FIGO early-stage disease, has been widely 
accepted and produces equivalent results. However, 
disparate prognoses have been observed in both SCC 
and ADC patients with the same stage based on FIGO 
guidelines. Moreover, an upward trending incidence 
of ADC has been reported in many countries. This 
upward trend is particularly evident among women 
under age 40. The proportion of ADC has doubled 
over the past decade and accounts for approximately 
25% of all cases of cervical cancer. The poorer 
prognosis of ADC patients compared to those with 
SCC raises the question of whether the current 
standard treatment for patients with SCC is suitable for 
those with ADC Thus, it is of great importance to 
determine the prognostic factors involved in ADC so 
as to establish a framework for new therapeutic 
strategies. 
In the literature, the prognostic significance of some 
clinicopathological factors still remains controversial. 
The aim of the present retrospective study was to 
clarify the clinicopathological factors for predicting 
the prognosis for ADC and squamous cell carcinoma.  
MATERIAL & METHODS:  
All consecutive patients diagnosed with the FIGO 
staging of squamous cell carcinoma and ADC of the 
uterine cervix are treated at The First Affiliated 
Hospital of Xinjiang Medical University, China 
between October 2014 and January 2019 were eligible 
for this study retrospectively. A sum of 186new 
patients with essential intrusive cervical carcinoma 
were treated by radiotherapy, chemotherapy and 
radiography at the First affiliated hospital of Xinjiang 
Medical University, China. Of these patients, 99.0 % 
had unadulterated squamous cell carcinoma (SCC). 
The remaining 1 % patient with adenocarcinoma were 
rejected from this examination. After an underlying 
clinical examination, all patients experienced a total 
arranging workup, including a total blood tally, blood 
science tests, chest radiography, and biopsy of the 
cervical tumor. Cystoscopy and dribble implantation 
pyelography were performed in all patients; just in 
suspicious case was sigmoidoscopy performed [2] [6].  
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The quantities of patients are shown by malignancy 
arranges in Table 1. Stages were resolved by the 
International Federation of Gynecology and Obstetrics 
criteria. Patients with removed metastasis (ie organize 
IVb cervical carcinoma) before treatment and patients 
treated by chemotherapy before radiation were 
prohibited. 
Table 1: Numbers of Patient by cancer staging.  
Sr. No Clinical Stage No. of patients % of patients 
1. 
2. 
IA 
IB 
18 
33 
9.7% 
17.7 % 
3. IIA 52 28 % 
4. 
5. 
IIB 
IIA+B 
49 
11 
26.3% 
5.9% 
6. IIIA 9 4.8 % 
7. IIIB 9 4.8 % 
8. IVA 5 2.7 % 
 Total 186 100 % 
 
 
 
 
Graph-1 Staging percentage 
 
Patient  
Data were obtained from the First Affiliated Hospital 
of Xinjiang Medical University, China between 
October 2014 and January 2019 that is maintained by 
the National Cancer Institute and consists of 
186population-based cancer registries. We included 
squamous cell carcinoma patients from 2014 to 2019 
and permission to access research data files was 
obtained.  
Statistical Analysis:  
Factual examinations were performed with the SPSS 
16.0 programming bundle (IBM, Armonk, NY). 
Synopsis insights are displayed as frequencies and 
rates. The randomization of medical clinic records was 
performed through the probabilistic examining 
process with substitution, and a test for 
straightforward irregular examples was utilized. The 
example comprised of CC patients who were conceded 
somewhere in the range of 2014 and 2019 and whose 
restorative records included histopathological or 
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anatomopathological examinations. Deficient records 
or cases in which treatment was deserted before the 
consummation of the five-year follow-up time were 
barred. The season of survival was determined as the 
interim between the date of conclusion (by biopsy or 
medical procedure) in the emergency clinic record and 
the date of death or the finish of development. The 
most extreme follow-up time was five years; the 
instance of any patient who stayed alive after this point 
was shut. 
Overall survival (OS) and relapse-free survival (RFS) 
were obtained by the Kaplan–Meier method for 
different groups. The Kaplan–Meier estimator, also 
known as the product limit estimator, is a non-
parametric statistic used to estimate 
the survival function from lifetime data. In our 
research, it is often used to measure the fraction of 
patients living for a certain amount of time after 
treatment. The log-rank test was used to compare 
survival curves. Variables that showed a significant 
association with survival were included in multivariate 
analysis based on the Cox proportional–hazard model. 
Sites of recurrence were classified as local if detected 
in the pelvis or vagina, and distant if detected in extra 
pelvic locations.  
RESULT:  
Patient numbers by cancer stage of the study are 
shown in Table 1. Mean age of the patients was 46 
years (range, 18–85 years). Disease-specific survival 
curves are shown according to cancer stages in Figure 
1. The cumulative 5-year survival rates for stages Ib, 
II, and III/IVa disease were 93.5, 77.0, and 60.3%, 
respectively.  
 
 
Figure 1: Disease-specific survival curves for five years and ten years. 
Percentage of prevalence as per the age distribution:  
Percentage rates are a useful tool for comparing various characters among various populations suffering from various 
diseases having different consequences.  Here a detailed description has been given of the patients along with their 
age distribution as well as the percentage of prevalence of the diseases in various age group.   
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Table 2. Patients from different age groups 
Different age parameters  Percentage of Prevalence in 
decades of life (%) 
Age (Year)  
Median Range  46  
26-35 1.6 % 
36-45 21 % 
46-55 38.2 % 
56-65 29 % 
66-75 8.6 % 
76-85 1.6 % 
  
Table 2: Percentage of prevalence as per the age distribution Differentiation of Cervical Cancer (CC) based on 
different stage of CC 
 
Graph-2 Age percentage 
 
Patients were divided into different groups depending upon the different stages of cervical cancer they are going 
through in order to treat them in better way. They were divided in various groups like well differentiated CC, 
moderately differentiated and poorly differentiated respectively. Their detailed percentage occurrence is given below;  
Table 3: Differentiation of Cervical Cancer (CC) based on different stage of Lesions. 
Well differentiated CC 67.72  % 
Moderately differentiated CC 5.82 % 
Poorly/undifferentiated CC 26.46 % 
 TOTAL 100 % 
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Poorly differentiated cells may be similar in appearance to the original cells from which they developed, but they 
may not be able to do all of the jobs expected of healthy immune cells. Cells that are poorly differentiated are less 
mature, more likely to grow fast, and also generally more susceptible to chemotherapy. 
Well-differentiated cells closely resemble mature cells and so they tend to divide and grow more slowly. Malignant 
cells that are well differentiated, like their normal counterparts, tend to grow slowly. 
In some cases, information about differentiation can influence the prognosis and inform the treatment decision. In 
general, “well differentiated” translates to a lower grade cancer, while “poorly differentiated” translates to a higher-
grade malignancy. 
Moderately differentiated, Grade 2 
Intermediate forms of tumor with both good and bad prognosis 
 
Tumor Size (T) 
The letter "T" plus a number (0 to 4) describes the size and location of the tumor, including how much the tumor has 
grown into nearby tissues. Tumor size is measured in centimeters (cm). A centimeter is roughly equal to the width of 
a standard pen or pencil. A larger tumor or a tumor that has grown more deeply into the surrounding tissue receives a 
higher number [9]. The details are given below; 
Table 4: Tumor size distribution. 
  size (cm)  Parameters 3.9 (0.1-7.4) 
≤4 cm 74.07 % 
>4 cm 25.93 % 
 
Different Treatment options in patients of certain groups. 
Most squamous cell carcinoma cases are found and treated at an early stage, where they are mostly treated with 
surgical treatment total/subtotal hysterectomy and in case of late stage cancer they are treated with radiology or 
chemotherapy. Larger squamous cell cancers are harder to treat, and fast-growing cancers have a higher risk of 
coming back. In rare cases, squamous cell cancers can spread to lymph nodes or distant parts of the body. If this 
happens, treatments such as radiation therapy and/or chemotherapy may be needed [7] [8]. The percentage of various 
patients’ treatment with different techniques is given in the table below;  
Table 5: Different Treatment options in patients of certain groups. 
Status Frequency Percentage 
 Give up 4 2.2 
Surgical 123 66.1 
Radiotherapy & chemotherapy 17 9.1 
Radiotherapy 6 3.2 
Chemotherapy 35 18.8 
Surgery & Chemotherapy 1 .5 
 
Lymphadenectomy  
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Table 6:  Lyphdenectomy status 
No 103 (54.50) 
Yes 86 (45.50) 
Lymph Nodes –ve 97 (51.32) 
Lymph Nodes +ve  92(48.68) 
*Lymphadenectomy has no significant effects on survival outcome in patients received. 
DISCUSSION: 
Most of the knowledge gained during this research 
study was from the single-institution reports with a 
limited numbers of patients. Here, we identified some 
patients of histologically confirmed squamous cell 
carcinoma between different ages from the Hospitals 
registry. Previous studies have showed that squamous 
cell carcinoma accounts cervix cancers. The incidence 
rate in our study was 0.7%, which is lower than 
previously reported. About 26.4% of squamous cell 
carcinoma patients have poorly or undifferentiated 
histology. Therefore, it is important to distinguish 
squamous cell cervical carcinoma from poorly 
differentiated cervical cancer [10]. 
We can see that there are patients who are suffering 
from cervical cancer and they get medical treatment 
according to their stages some patients are suffer from 
1st stage of cervical cancer and some suffer from 
higher stages they all get surgery according to their 
conditions and then some patients get chemotherapy if 
we see according to ages so we have some sample of 
ages between 18 to 85 age. Most of the patients 
consisting of 28% of the patients were suffering with 
the Stage IIA clinical stage followed by stage IIB with 
26.3%patients. The patients were treated using various 
treatment options depending on their complications. 
3.2% patients had gone through Radiotherapy along 
with the Hysterectomy 66.1% and chemotherapy 
18.8% for the recovery [12] [14]. 
In most of the patients the clinical symptoms are 
abnormal vaginal bleeding or a few of them with 
vaginal discharge and they get radiotherapy and 
chemotherapy as treatment in our data mostly patient 
cancer type is Squamous cell carcinoma with 
abnormal vaginal bleeding symptoms and after these 
patient there are some patient who are suffer from 
Papillary Squamous cell carcinoma cancer type and 
they get treatment as surgery with chemotherapy and 
there clinical symptoms are contact bleeding some 
patients are suffering from pelvic lymph node and they 
also get treatment radiotherapy with chemotherapy.  
According to our data most of the patients who were 
suffering from this cancer are falling in between 45 to 
55 age so they get treatment according to their clinical 
symptoms with different stages 1A 11A 1B 11B and 
IA1[13]. 
CONCLUSION:  
In conclusion, squamous cell carcinoma is a disease 
with aggressive characteristics and prone to 
metastasize and is dismal in prognosis. The conclusion 
of this study is that more than 95 % of the cervix 
patients were suffering with the squamous cell 
carcinoma and were treated using various techniques. 
The survival outcome of the patients remained high in 
the study that is mostly due to more patients of primary 
stages also the survival is associated with age and our 
study population mean age falls between 45 to 55 
years. The survival rate of patients who have this 
disease is associated with increasing age, stage of the 
disease and treatment by primary radiotherapy. 
This is a limited study and more studies are needed to 
confirm our results and develop optimal management 
of squamous cell carcinoma of the cervix. There are 
several recommendations of this study. The first is the 
inherent biases existing in any retrospective study. 
However, the major strength of the present study is the 
ability to describe the epidemiology, 
clinicopathological features, treatment trends, and 
survival outcomes of this disease using a population-
based study. Second, Hospital database lacked the 
information about centralized pathologic review, 
pathological factors (margin status and parametrical 
invasion details of radiation therapy and 
chemotherapy, and the data of local and distant 
recurrence. In addition, there is little information 
available to guide the choice of treatment in certain 
patients.  
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